News
GLPG
32.01
-2.86%
-0.94
BofA downgrades Galapagos to Underperform over lack of catalysts in the near term
BofA downgrades Galapagos to Underperform over lack of catalysts in the near term. American depository shares fell 2.1% in premarket trade. Firm's key cancer pipeline has three to four years to market and unclear differentiation in competitive end-markets.
Seeking Alpha · 5h ago
Galapagos Price Target Cut to $31.00/Share From $41.00 by B of A Securities
Dow Jones · 7h ago
Galapagos Cut to Underperform From Neutral by B of A Securities
Dow Jones · 7h ago
B of A Securities Downgrades Galapagos to Underperform, Lowers Price Target to $31
Benzinga · 7h ago
Praxis (PRAX) Surges on Positive Epilepsy Study Results
NASDAQ · 1d ago
Regeneron's (REGN) Lymphoma Candidate Rejected by the FDA
NASDAQ · 2d ago
Weekly Report: what happened at GLPG last week (0318-0322)?
Weekly Report · 3d ago
Earnings week ahead: Walgreens Boots Alliance, Carnival, GameStop and more
Several key companies are set to release their earnings reports for the week of March 25 to 29. Walgreens Boots Alliance, Carnival, GameStop and more are among the companies scheduled to report next week. The week is shortened by a market holiday on Friday and will be shortened to one day.
Seeking Alpha · 4d ago
Lifecore (LFCR) Down 30% on Ending Strategic Review With No Deal
NASDAQ · 03/21 16:40
Bayer's (BAYRY) Elinzanetant Meets Goals in Third Phase III Study
NASDAQ · 03/20 18:00
Galapagos Enters Oversold Territory (GLPG)
NASDAQ · 03/18 20:27
Weekly Report: what happened at GLPG last week (0311-0315)?
Weekly Report · 03/18 09:27
Weekly Report: what happened at GLPG last week (0304-0308)?
Weekly Report · 03/11 09:26
EUROPE RESEARCH ROUNDUP-Aena SME SA, Arkema SA, ITV Plc
Analysts revise ratings and price targets on several European companies. Aena SME SA, Arkema SA, ITV Plc and ITV raise their targets. HSBC cuts target price to EUR 107 from EUR 111 for ITV. A.G. Barr raises to equal weight from underweight.
Reuters · 03/08 07:03
Galapagos: Pipeline Still Progressing Despite Financial Volatility
Galapagos has managed to curtail its R&D and G&A expenses, demonstrating efficient cost management. The company has strategically focused on oncology and immunology. Galapagos is investing in CAR-T cell therapies, with promising early data indicating progress in its unique manufacturing platform.
Seeking Alpha · 03/07 16:30
Galapagos Coverage Assumed by Morgan Stanley at Equal-Weight
Dow Jones · 03/07 09:30
Morgan Stanley Assumes Galapagos at Equal-Weight, Announces Price Target of $38
Benzinga · 03/07 09:20
Weekly Report: what happened at GLPG last week (0226-0301)?
Weekly Report · 03/04 09:27
Galapagos (GLPG) Gets a Hold from RBC Capital
TipRanks · 02/27 01:45
Weekly Report: what happened at GLPG last week (0219-0223)?
Weekly Report · 02/26 09:29
More
Webull provides a variety of real-time GLPG stock news. You can receive the latest news about Galapagos Nv through multiple platforms. This information may help you make smarter investment decisions.
About GLPG
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. It develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve quality of life of patients across the globe. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The Company acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.